Publication: Protective roles of melatonin against the amyloid-dependent development of Alzheimer's disease: A critical review
Issued Date
2018-08-01
Resource Type
ISSN
10961186
10436618
10436618
Other identifier(s)
2-s2.0-85049521142
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacological Research. Vol.134, (2018), 223-237
Suggested Citation
Bruno Vincent Protective roles of melatonin against the amyloid-dependent development of Alzheimer's disease: A critical review. Pharmacological Research. Vol.134, (2018), 223-237. doi:10.1016/j.phrs.2018.06.011 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/47306
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Protective roles of melatonin against the amyloid-dependent development of Alzheimer's disease: A critical review
Author(s)
Other Contributor(s)
Abstract
© 2018 Elsevier Ltd Since its discovery almost 60 years ago by Lerner and colleagues, melatonin (N-acetyl-5-metoxytryptamine), a hormone mainly produced in the pineal gland, has been the subject of numerous investigations aimed at establishing its physiological functions. The subsequent seminal observation that melatonin levels decrease during normal aging, combined with the facts that AD patients show melatonin deficits when compared to age-matched controls and that the extent of melatonin loss in the cerebrospinal fluid parallels the progression of the disease, was the starting point of a series of studies, conducted during the past 20 years, aimed at determining whether this non-peptide hormone could reasonably be considered as a possible promising anti-AD compound and at establishing through which mechanisms it can control the time course of the disease. In this context, particular attention has been paid to the amyloid peptide (Aβ), which, according to the now well accepted “amyloid cascade” hypothesis, is a key element of the pathology. Indeed, works performed in vitro and in vivo, thanks to the development of reliable mouse models of the pathology, consistently proved melatonin as an efficient anti-amyloid remedy when considering all the steps of Aβ biology (production, conformational changes, oligomerization, fibrillation and ultimately senile plaque formation). This review proposes to draw up a detailed inventory of our current knowledge on the subject with a particular focus on the recent advances in the field. Given the fact that melatonin conveys very few secondary effects, it is nowadays possible to seriously envision melatonin as an effective preventive anti-AD molecule.